A detailed history of Black Rock Inc. transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 282,389 shares of ETON stock, worth $3.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
282,389
Previous 282,952 0.2%
Holding current value
$3.06 Million
Previous $1.06 Million 12.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.06 - $3.75 $1,722 - $2,111
-563 Reduced 0.2%
282,389 $929,000
Q1 2024

May 10, 2024

SELL
$3.48 - $5.03 $4,485 - $6,483
-1,289 Reduced 0.45%
282,952 $1.06 Million
Q4 2023

Feb 13, 2024

SELL
$3.45 - $4.66 $3,225 - $4,357
-935 Reduced 0.33%
284,241 $1.24 Million
Q3 2023

Nov 13, 2023

SELL
$2.55 - $5.63 $33,274 - $73,465
-13,049 Reduced 4.38%
285,176 $1.19 Million
Q2 2023

Aug 11, 2023

BUY
$3.32 - $4.04 $18,459 - $22,462
5,560 Added 1.9%
298,225 $1.04 Million
Q1 2023

May 12, 2023

BUY
$2.89 - $4.1 $5,531 - $7,847
1,914 Added 0.66%
292,665 $1.13 Million
Q4 2022

Feb 13, 2023

BUY
$2.02 - $3.25 $1,191 - $1,917
590 Added 0.2%
290,751 $819,000
Q3 2022

Nov 14, 2022

SELL
$2.04 - $3.03 $3,166 - $4,702
-1,552 Reduced 0.53%
290,161 $610,000
Q2 2022

Aug 12, 2022

SELL
$2.55 - $4.38 $12,306 - $21,137
-4,826 Reduced 1.63%
291,713 $764,000
Q1 2022

May 12, 2022

SELL
$3.43 - $4.69 $8,242 - $11,270
-2,403 Reduced 0.8%
296,539 $1.29 Million
Q4 2021

Feb 10, 2022

SELL
$3.66 - $6.59 $7,155 - $12,883
-1,955 Reduced 0.65%
298,942 $1.28 Million
Q3 2021

Nov 09, 2021

SELL
$4.2 - $6.26 $676 - $1,007
-161 Reduced 0.05%
300,897 $1.52 Million
Q2 2021

Aug 11, 2021

BUY
$5.71 - $8.85 $1.72 Million - $2.66 Million
301,058 New
301,058 $1.86 Million

Others Institutions Holding ETON

About Eton Pharmaceuticals, Inc.


  • Ticker ETON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,297,000
  • Market Cap $274M
  • Description
  • Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...
More about ETON
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.